• Confocal immunofluorescent analysis of MDA-MB-453 cells (left) and MDA-MB-231 cells (right), using HER2/ErbB2 (29D8) Rabbit mAb (green). (cellsignal.com)
  • Flow cytometric analysis of MDA-MB-468 cells (blue) and SKBR3 cells (green) using HER2/ErbB2 (29D8) Rabbit mAb (solid lines) or a concentration-matched Rabbit (DA1E) mAb IgG XP ® Isotype Control #3900 (dashed lines). (cellsignal.com)
  • Western blot analysis of cell extracts from various cell lines, using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)
  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)
  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (29D8) RmAb in the presence of control peptide (left) or HER2/ErbB2 Blocking Peptide #1059 (right). (cellsignal.com)
  • Immunohistochemical analysis of paraffin-embedded SKBr3 (high HER2) (left), MDA-MB-453 (moderate HER2) (middle) and MDA-MB-468 (low HER2) (right), using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)
  • The ErbB protein family consists of 4 members ErbB-1, also named epidermal growth factor receptor (EGFR) ErbB-2, also named HER2 in humans and neu in rodents ErbB-3, also named HER3 ErbB-4, also named HER4 v-ErbBs are homologous to EGFR, but lack sequences within the ligand binding ectodomain. (wikipedia.org)
  • Receptor tyrosine-protein kinase erbB-2, also known as HER2/Neu (human epidermal growth factor receptor 2), is a member of the human epidermal growth factor receptor family. (meridianbioscience.com)
  • Overexpression of HER2/Neu plays an essential role in the development and progression of specific subtypes of breast cancer. (meridianbioscience.com)
  • ERBB2 is a protein that is also known as HER2 (human epidermal growth factor receptor 2). (antibodyguide.com)
  • HER2 gene encodes a cell-surface glycoprotein tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. (biovisi.com)
  • HER2 is an oncogene and overexpression of unaltered HER2 coding sequences in NIH 3T3 cells results in cellular transformation and tumorigenesis. (biovisi.com)
  • HER2 is amplified in about 30% of primary human breast malignancies and overexpression of HER2 is associated with the most aggressive tumors that show uncontrolled proliferation, resistance to apoptosis and increased motility. (biovisi.com)
  • Omdat bij 70% van de alvleesklierkankerpatiënten de HER2-Neu expressie oververtegenwoordigd is en juist Herceptin bij borstkankerpatiënten met deze receptor uitstekende resultaten laat zien zijn deze trials opgezet. (kanker-actueel.nl)
  • Although neither kinase-dead human epidermal growth factor receptor (HER)3 nor orphan HER2 can be activated by HER-related ligands on their own, the formation of HER2/HER3 heterodimers creates the most mitogenic and transforming receptor complex within the HER (erbB) family of transmembrane receptor tyrosine kinases. (biomedcentral.com)
  • It remains to be elucidated whether reactivation of HER3 signalling can also account for the poor efficacy of HER TKIs in treating breast carcinomas that contain low overall levels of HER2 receptors. (biomedcentral.com)
  • However, it appears that regardless of the mechanism that triggers the formation of oncogenic HER2/HER3 heterodimers (HER2 over-expression or overall low HER2 but high levels of the HER3 ligand heregulin), HER3 transphosphorylation is a common response of breast cancer cells upon treatment with current inhibitors of the HER receptor tyrosine kinase network. (biomedcentral.com)
  • Receptor tyrosine-protein kinase ERBB-2 (HER2 - human epidermal growth factor receptor 2) is considered as a marker of aggressiveness in the case of breast cancer in primary tumours as well as in corresponding metastases. (biomedres.us)
  • Neratinib is an investigational, orally administered, irreversible inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. (her2support.org)
  • HER2 positive breast cancer is identified by the overexpression of human epidermal growth factor receptor-2 (HER2) protein in tumor tissue and results in an increased rate of cell proliferation. (her2support.org)
  • 1 The human epidermal growth factor receptor 2 (HER2 or ErbB2) is a tyrosine kinase receptor that belongs to the EGFR (ErbB) family and is sometimes implicated in breast, lung, and other cancers. (mdforlives.com)
  • An estimated 2-6% of NSCLC cases have a mutation in the HER2 oncogene, and others have overexpression or amplification of HER2. (mdforlives.com)
  • Human epidermal growth factor receptor 2 (HER2) bound to a targeted therapeutic agent. (mdforlives.com)
  • HER2 (ErbB2) is found on the surface of various cancer cells and is the target of several therapeutic agents. (mdforlives.com)
  • Other examples are trastuzumab deruxtecan (T-Dxd) and ado-trastuzumab emtansine (T-DM1), which are HER2-targeted antibody-drug conjugates in trials for NSCLC that involves HER2 overexpression or mutation. (mdforlives.com)
  • Antibody-drug conjugates are finding success in Phase 2 clinical trials for the treatment of NSCLC that involves HER2 overexpression or HER2 mutation. (mdforlives.com)
  • Introduction Epidermal development element receptor (EGFR) was the 1st discovered from the ErbB category of receptor tyrosine kinases with a total of four users: Erbb1/EGFR, ErbB2/Her2, ErbB3 and ErbB4. (bio-biz-navi.com)
  • The human epidermal growth factor receptor 2 (HER2) status is important in the medical management of patients with various human cancers. (ijmpo.org)
  • Amplification of the human epidermal growth factor receptor 2 ( HER2 ) gene and overexpression of the HER2 protein is found in 15%-20% of patients with gastric and gastroesophageal junction cancer. (wjgnet.com)
  • The degree of HER2 overexpression and amplification varies with the location of the carcinoma, with higher expression in the gastroesophageal and proximal parts compared to the distal parts of the stomach. (wjgnet.com)
  • Further, HER2 overexpression and amplification also seems to be related to the Lauren histological classification, with higher levels found in the intestinal phenotype compared to the diffuse and mixed types. (wjgnet.com)
  • The prognostic properties of HER2 overexpression and amplification are still under debate, but a large number of studies seem to indicate that HER2 is a negative prognostic factor. (wjgnet.com)
  • Patients with a strong overexpression of the HER2 protein (IHC3+) specifically benefited from the treatment, with a median overall survival of 17.9 mo. (wjgnet.com)
  • The proto-oncogene designated erbB2 or HER2 encodes a 185-kilodalton transmembrane tyrosine kinase (p185erbB2), whose overexpression has been correlated with a poor prognosis in several human malignancies. (embl.de)
  • The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. (wikipedia.org)
  • Recently, we isolated a novel negative regulator of epidermal growth factor receptor (EGFR), termed EGFR-related protein (ERRP), whose expression attenuates EGFR activation. (aacrjournals.org)
  • In the current study, we examined the effects of recombinant ERRP on the growth and ligand-induced activation of multiple members of erbB family in three pancreatic cancer cell lines that express varying levels of EGFR and other member(s) of its family, specifically HER-2. (aacrjournals.org)
  • ERRP also inhibited ligand-induced activation of EGFR, HER-2, and HER-3 (ErbB3). (aacrjournals.org)
  • In contrast, Erbitux and Herceptin only partially or modestly inhibited activation of EGFR, HER-2, and HER-3. (aacrjournals.org)
  • It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. (antibodyguide.com)
  • It inhibits both ERBB2 and EGFR activity. (antibodyguide.com)
  • The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). (activemotif.com)
  • The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role in the pathogenesis of NSCLC. (bmj.com)
  • Alterations in receptor tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor 1, include overexpression, amplification or mutations. (bmj.com)
  • It has been proposed that oncogenes (EGFR (ERBB), MET) and tumor suppressors (PTEN, TP53) may also be capable of altering the vesicular release of tissue factor (TF) from cells [4-6]. (biomedres.us)
  • For NSCLC, much of the work in the last decade has been focussed on mutations of the epidermal growth factor receptor (EGFR) and on the abnormal fusion of the anaplastic lymphoma kinase (ALK) being inhibited successfully with EGFR tyrosine kinase inhibitors (TKI) and crizotinib respectively. (amegroups.org)
  • EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. (thermofisher.com)
  • EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. (thermofisher.com)
  • EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. (thermofisher.com)
  • Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. (thermofisher.com)
  • Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. (thermofisher.com)
  • Epidermal growth factor receptor ( EGFR , ErbB ) gene mutations are one of the most well-researched targets for lung cancer treatment. (mdforlives.com)
  • 1,2 EGFR tyrosine kinase inhibitors (EGFR TKI) are used as first-line treatments in advanced NSCLC cases where EGFR mutations are present. (mdforlives.com)
  • 1,2 Patritumab deruxtecan (HER3-DXd/U3-1402) is a HER3-targeted antibody-drug conjugate that showed anti-tumor activity and acceptable safety in patients with advanced NSCLC who are on EGFR TKI. (mdforlives.com)
  • 2,13 Monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are effective treatment options for a relatively small percentage of patients with NSCLC, but they are not recommended for patients with EGFR-mutated NSCLC. (mdforlives.com)
  • HER-2 (ErbB2) is a 185-kDa transmembrane tyrosine kinase with extensive homology to the epidermal growth factor receptor (EGFR). (touchoncology.com)
  • The epidermal growth factor receptor (EGFR) is among the most well-studied signaling pathways in cancer progression. (bio-biz-navi.com)
  • 2 Since its finding, EGFR continues to be characterized like a mediator of a multitude of signal transduction occasions that control cell proliferation, migration and success. (bio-biz-navi.com)
  • Overexpression of EGFR transforms NIH3T3 fibroblasts within an EGF-dependent way. (bio-biz-navi.com)
  • ErbB protein family signaling is important for development. (wikipedia.org)
  • The figure below shows the tridimensional structure of the ErbB family proteins, using the pdb files 1NQL (ErbB-1), 1S78 (ErbB-2), 1M6B (ErbB-3) and 2AHX (ErbB-4): The four members of the ErbB protein family are capable of forming homodimers, heterodimers, and possibly higher-order oligomers upon activation by a subset of potential growth factor ligands. (wikipedia.org)
  • The total-ErbB-2 antibody supplied in the FACE ErbB-2 Kits recognizes ErbB-2 protein regardless of its phosphorylation site. (activemotif.com)
  • In addition, it has also been shown that the level of fibronectin, a blood clotting associated protein is significantly increased in ERBB2-overexpressing MDA-MB231 cells [7]. (biomedres.us)
  • It was observed that overexpression of ERBB2 was able to modulate the level of several coagulation proteins, including protein C, Factor-X and TF, and the activities of TF and thrombomodulin, as well as the rate of clotting and thrombin activity. (biomedres.us)
  • The finding is the first time shown pro-tumour gene ERBB2 enable to modulate coagulation protein expression and clotting kinetics in breast cancer cells, it is via the PI3k/Akt pathways, which further supports the proposal that the state of the coagulation system in cancer is directly influenced by oncogenic transformation. (biomedres.us)
  • c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. (thieme-connect.de)
  • These mutations in receptors or protein kinases can stimulate a complex cascade of cross signalling pathways such as the RAS-RAF-MEK-ERK or MAPK, PI3K-AKT-mTOR or JAK-STAT pathways ( Figure 2 ) ( 3 , 4 , 7 , 18 , 20 ). (amegroups.org)
  • Of the 31 genes, the 21 upregulated genes were primarily associated with cell paracrine and intracellular signaling, transcription regulation and cell adhesion and migration, and their transcriptional products included transforming growth factor-β2 (TGF-β2), insulin-like growth factor-binding protein 2 and transcriptional factor AP-2α/γ ( 11 ). (spandidos-publications.com)
  • Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. (musc.edu)
  • The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: erythroblastic leukemia viral oncogene. (wikipedia.org)
  • This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. (creativebiolabs.net)
  • Many other genetic targets are under active research in lung cancer, including Kirsten rat sarcoma viral oncogene homolog (KRAS), c-mesenchymal-epithelial transition receptor (c-Met), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neurotrophic tyrosine receptor kinase (NTRK). (mdforlives.com)
  • The amplification of the HER-2 oncogene occurs in ~25% of breast cancer patients and is associated with diminished disease-free and overall survival. (touchoncology.com)
  • Notably, the ErbB1 and ErbB4 are the two most studied and intact among the family of ErbB proteins, Which forms functional intracellular tyrosine kinases. (wikipedia.org)
  • The epidermal growth factor receptor (ERBB1) and related family member HER-2/ neu (ERBB2) are often overexpressed in aggressive breast cancers and their overexpression is correlated with poor prognosis. (aacrjournals.org)
  • Using in vivo mouse models of breast cancer, we test the effects of ERBB1 and ERBB2 inhibitors AC480 and lapatinib, ERBB1 inhibitor gefitinib, and ERBB2 inhibitor AG825 on in vivo tumor cell invasive properties in mammary fat pad tumors. (aacrjournals.org)
  • ERBB1 and ERBB2 inhibition rapidly (within 3 h) inhibits both tumor cell motility and intravasation. (aacrjournals.org)
  • Using gefitinib, ERBB1 inhibition rapidly inhibits tumor cell motility and invasion but not intravasation, whereas ERBB2 inhibition by AG825 rapidly blocks intravasation. (aacrjournals.org)
  • ERBB1 and ERBB2 inhibition can rapidly block tumor cell invasive properties. (aacrjournals.org)
  • In addition, we differentiate for the first time the contributions of ERBB1 and ERBB2 to the key metastatic properties of in vivo tumor cell invasion and intravasation. (aacrjournals.org)
  • Novel therapeutic agents, in particular those that specifically target members of the human epidermal growth factor receptor (HER (ErbB1)) pathway, have shown encouraging therapeutic efficacy. (bmj.com)
  • EXPERIMENTAL DESIGN: Using in vivo mouse models of breast cancer, we test the effects of ERBB1 and ERBB2 inhibitors AC480 and lapatinib, ERBB1 inhibitor gefitinib, and ERBB2 inhibitor AG825 on in vivo tumor cell invasive properties in mammary fat pad tumors. (novartis.com)
  • Amplification and overexpression of this gene are also associated with multiple human cancers. (creativebiolabs.net)
  • Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. (activemotif.com)
  • ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. (thieme-connect.de)
  • 7 Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. (thieme-connect.de)
  • HER-2/neu amplification predicts poor survival in node-positive breast cancer. (thieme-connect.de)
  • 14 King C R, Kraus M H, Aaronson S A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. (thieme-connect.de)
  • Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. (musc.edu)
  • Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. (rochester.edu)
  • It is a complex process due to the domain specificity and nature of the members of ErbB family. (wikipedia.org)
  • ErbB2 has no known binding ligand and absent of an active kinase domain in ErbB3 make this duo preferable to form heterodimers & share each other's active domains to activate transphosphorylation of the tyrosine kinases. (wikipedia.org)
  • 1, 2 Most studies of MUC1 expression in breast carcinomas have shown that increased membrane MUC1 mucin expression on the apical cell surface is associated with a better prognosis (reviewed in Rahn and colleagues 2 ), whereas circumferential staining in tumour cell cytoplasm is associated with a worse prognosis. (bmj.com)
  • The HER-2/neu onkogene may play a role in the prognosis and management of patients with breast cancer. (thieme-connect.de)
  • Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data. (thieme-connect.de)
  • 5 Beckmann M W, Niederacher D, Schnurch H G, Bender H G. The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities. (thieme-connect.de)
  • Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor ® 488 Conjugate) #4412 was used as a secondary antibody. (cellsignal.com)
  • Trastuzumab (Herceptin) is an antibody that targets ERBB2 and has been approved for the treatment of breast cancer. (antibodyguide.com)
  • The Y877 kit contains phospho-ErbB-2 antibody that recognizes ErbB-2 only when phosphorylated at Tyr877, while the Y1248 kit provides a phospho-antibody that recognizes ErbB-2 only when phosphorylated at Tyr1248. (activemotif.com)
  • Each kit contains a total-ErbB-2 antibody that recognizes ErbB-2 regardless of its phosphorylation state. (activemotif.com)
  • The FACE ErbB-2 (Y877) Kit contains a phospho-ErbB-2 antibody that was raised in rabbit against a synthetic phospho-peptide corresponding to residues surrounding phosphorylated Tyr877 of human ErbB-2 and recognizes ErbB-2 only when phosphorylated at Tyr877. (activemotif.com)
  • This cell surface receptor can be targeted specifically by the neutralizing antibody Herceptintrade mark. (kanker-actueel.nl)
  • While it has been recognised for some time that overexpression of HER-2 is a poor prognostic factor in breast cancer, it was the advent of trastuzumab, a humanised monoclonal antibody directed against the extracellular domain of HER-2, that has allowed clinicians to better understand the natural history of HER-2-positive metastatic breast cancer. (touchoncology.com)
  • The primary antihuman antibody against c-erbB-2 oncoprotein (DAKO Diagnostics) was used for IHC. (ijmpo.org)
  • ErbB-1 and ErbB-2 are found in many human cancers, and their excessive signaling may be critical factors in the development and malignancy of these tumors. (wikipedia.org)
  • 1 ] [ 2 ] These tumors develop more in middle and late adulthood. (ijmpo.org)
  • 3 ] Most meningiomas are benign tumors, but up to 15% are atypical, and 2% malignant according to the World Health Organization histological criteria reported in 2016. (ijmpo.org)
  • The prostaglandin-endoperoxide synthase 2 gene (PTGS2), which encodes cyclooxygenase-2, was found to upregulate the expression of TGF-β2 ( 14 ). (spandidos-publications.com)
  • The erbB family of receptor tyrosine kinases plays critical roles in human cancers, including pancreatic cancer. (aacrjournals.org)
  • ErbB2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of human cancers , including cancers of the breast. (her2support.org)
  • Such examples include trastuzumab for HER-2 over-expressing breast cancer and vemurafenib for BRAF-mutant melanoma ( 9 , 10 ). (amegroups.org)
  • The use of trastuzumab when given with chemotherapy improves response rates and progression-free and overall survival of patients with HER-2-positive metastatic breast cancer. (touchoncology.com)
  • The ability ('+') or inability ('-') of each growth factor to activate each of the ErbB receptors is shown in the table below: The dimerization occurs after ligand bind to the extracellular domain of the ErbB monomers and monomer-monomer interaction establishes activating the activation loop in a kinase domain, that activates the further process of transphosphorylation of the specific tyrosine kinases in the kinase domain of ErbB's intracellular part. (wikipedia.org)
  • It binds to the extracellular domain of ERBB2 and inhibits its activity. (antibodyguide.com)
  • 1 ErbB users type homo- and heterodimeric cell-surface receptors with original extracellular domains yielding ligand-binding specificity. (bio-biz-navi.com)
  • Each FACE ErbB-2 Kit provides 96 rxns each of 2 antibodies that enable you to monitor and compare the levels of both phosphorylated and total ErbB-2. (activemotif.com)
  • Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. (thieme-connect.de)
  • Translational research advances now allow such mutations to be inhibited by either receptor monoclonal antibodies (mAb) or small molecule tyrosine kinase inhibitors (TKI). (amegroups.org)
  • The intracellular/cytoplasmic region of the ErbB receptor consists mainly of three subdomains: A juxtamembrane with approximately 40 residues, a kinase domain containing approximately 260 residues and a C-terminal domain of 220-350 amino acid residues that become activated via phosphorylation of its tyrosine residues that mediates interactions of other ErbB proteins and downstream signaling molecules. (wikipedia.org)
  • Such effects were found to be mediated by PI3k/ Akt signaling pathways since the increased these ERBB2 sensitive coagulation proteins in a way that was commensurate with the activity of p-ERK and p-Akt. (biomedres.us)
  • In line with this conclusion it was also observed that the expression of coagulation proteins corresponded with the level of expression of ERBB2 in three 'native' breast cancer cell lines (human enriched breast cancer stem cell (CSC), MDA-MB231 and MCF-7). (biomedres.us)
  • Discovering a specific agent, which targets multiple members of the erbB family, would be important in pancreatic cancer therapy. (aacrjournals.org)
  • Lapatinib (Tykerb) is another drug that targets ERBB2. (antibodyguide.com)
  • Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments. (activemotif.com)
  • MA5-14485 targets Epidermal Growth Factor Receptor in IHC (P) applications and shows reactivity with Human samples. (thermofisher.com)
  • Clinical studies using ERBB inhibitors have focused on tumor growth effects, but ERBBs can contribute to malignancy independent of their effects on tumor growth. (aacrjournals.org)
  • Our studies were designed to evaluate the effect of ERBB inhibition on tumor cell motility and intravasation in vivo using clinically relevant small-molecule inhibitors. (aacrjournals.org)
  • Also, the growth-inhibitory effects of HER1/2 tyrosine kinase inhibitors (TKIs) were previously found to be attenuated in the presence of heregulin, which is a high-affinity combinatorial ligand for HER3. (biomedcentral.com)
  • Meantime ERBB2 inhibitors were also used for further confirmation. (biomedres.us)
  • To investigate a possible modulatory role of ERBB2 in the procoagulant status of breast cancer cells, a line of ERBB2 overexpressing human breast cancer MCF-7 cells (MCF-7 ERBB2+) and human normal mammary MCF-12a cells (MCF-12a ERBB2+) respectively, were established by transfection with an ERBB2 plasmid (Addgene, Cambridge, USA) in our lab. (biomedres.us)
  • erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. (musc.edu)
  • Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. (musc.edu)
  • accepted choices are somatostatin analogs, peptide receptor radionuclide therapy, everolimus and chemotherapy. (springeropen.com)
  • Recently, several novel agents targeting growth factor receptors, angiogenic pathways, adhesion molecules and mediators of intracellular signal transduction have been clinically explored. (docksci.com)
  • Activation of the tyrosine kinase domain leads to the activation of the whole range of downstream signaling pathways like PLCγ, ERK 1/2, p38 MAPK, PI3-K/Akt and more with the cell. (wikipedia.org)
  • The enhancement in metastatic properties was also found to occur via activation of ERBB2 receptor signaling pathways [2]. (biomedres.us)
  • It soon became clear that patients with HER-2-overexpressing metastatic breast cancer were at high risk of developing CNS involvement. (touchoncology.com)
  • Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. (activemotif.com)
  • Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. (musc.edu)
  • Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. (creativebiolabs.net)
  • All four ErbB receptor family members are nearly same in the structure having single-chain of modular glycoproteins. (wikipedia.org)
  • erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. (musc.edu)
  • In particular, the overexpression of ERBB2 enhances the properties of tumour cells associated with increased cancer metastasis (invasiveness, angiogenicity, enhanced survival). (biomedres.us)
  • 2 There is only limited knowledge of the factors that predict for the development of CNS metastasis, but the main ones reported include young age, African ethnicity, oestrogen receptor (OR)-negativity, HER 2 -positivity, high tumour grade and BRCA 1 phenotype. (touchoncology.com)
  • PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. (musc.edu)
  • Gene expression profiling of ErbB receptor and ligand-dependent transcription. (rochester.edu)
  • ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. (activemotif.com)
  • The notion that breast cancer disease can be viewed as a biological process that is driven by overactive human epidermal growth factor receptor (HER)1/2 receptor tyrosine kinases (RTKs) has led to development of various anti-HER tyrosine kinase agents. (biomedcentral.com)
  • 2 Barnes D M, Lammie G A, Millis R R, Gullick W L, Allen D S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. (thieme-connect.de)
  • p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal. (musc.edu)
  • Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. (musc.edu)
  • This finding could indicate that HER-2/neu expression is a new independent prognostic factor. (thieme-connect.de)
  • ERBB2 is overexpressed in many types of cancer, including breast cancer, ovarian cancer, and gastric cancer. (antibodyguide.com)